Alzheimer's disease neuropathology is thought to spread across anatomically and functionally connected brain regions. However, the precise sequence of spread remains ambiguous. The prevailing model posits that Alzheimer's neurodegeneration starts in the entorhinal cortices, before spreading to temporoparietal cortex. Challenging this model, we previously provided evidence that degeneration within the nucleus basalis of Meynert (NbM), a subregion of the basal forebrain heavily populated by cortically projecting cholinergic neurons, precedes and predicts entorhinal degeneration (Schmitz and Spreng, 2016) . There have been few systematic attempts at directly comparing staging models using in vivo longitudinal biomarker data, and determining if these comparisons generalize across independent samples. Here we addressed the sequence of pathological staging in Alzheimer's disease using two independent samples of the Alzheimer's Disease Neuroimaging Initiative (N1 = 284; N2 = 553) with harmonized CSF assays of amyloid (Aβ) and hyperphosphorylated tau (pTau), and longitudinal structural MRI data over two years.
Introduction
Alzheimer's disease neuropathology progresses in stages, with certain brain regions affected by neuronal deposition of insoluble amyloid (Aβ) and hyper phosphorylated tau (pTau) before others. The asymmetrical progression of Alzheimer's disease neuropathology in different brain regions may reflect selective neuronal vulnerabilities local to each region (Mattson and Magnus, 2006; Saxena and Caroni, 2011; Wu et al., 2014; Schmitz and Nathan Spreng, 2016) . However, evidence in both mouse models of Alzheimer's disease (De Calignon et al., 2012; Liu et al., 2012) and in human Alzheimer's disease patients (Schmitz et al., 2018; Sepulcre et al., 2018) indicates that neuropathology also spreads across anatomically and functionally connected brain regions. It is therefore possible that pathologies arising from selective neuronal vulnerability local to a given brain region might precede and predispose the subsequent spread of pathology across networks (Warren et al., 2013) . Despite these observations, the precise sequence of neuropathological spread and its relationship with neurodegeneration during the earliest stages of disease remains ambiguous, and can only be resolved with in vivo longitudinal data integrating measures of proteinopathy and microstructural change. Moreover, there have been few systematic attempts at generalizing staging models across independent samples, which limits their clinical utility.
Determining when and why certain brain regions are affected in the course of Alzheimer's disease is essential for understanding the mechanistic basis of disease progression, accurately staging the disease, and identifying individuals for early therapeutic interventions. The prevailing staging model posits that abnormal Aβ and pTau accumulation starts in the entorhinal cortices (Braak and Braak, 1991; Corder et al., 2000; Braak et al., 2006) , before spreading to interconnected areas of medial temporal and posterior parietal cortex. The selective vulnerability of neurons in the entorhinal cortex to these proteinopathies is attributed to their high metabolic activity, the complexity of their axonal projections and the lifelong maintenance of their axonal plasticity (Mattson and Magnus, 2006; Liu et al., 2012; Khan et al., 2014; Wu et al., 2014; Roussarie et al., 2018) . One individual spiny stellate neuron in layer II of the entorhinal cortex innervates the entire transverse axis of the dentate gyrus, CA2/CA3 and the subiculum (Tamamaki and Nojyo, 1993) . Under a recent framework, amyloid pathology in entorhinal neurons potentiates hyper-phosphorylation of tau proteins ; Khan et al., 2014; Wu et al., 2016) , which then spread via trans-synaptic mechanisms to distal neocortical areas which receive inputs from EC; i.e. the EC→Neocortical model. See Figure 1A .
Challenging the EC→Neocortical model, we have provided initial evidence that degeneration within the nucleus basalis of Meynert (NbM), a subregion of the basal forebrain, precedes and predicts degeneration in the EC (Schmitz and Spreng, 2016) . The NbM (also referred to as Ch4 in Mesulam's nomenclature (Mesulam, 1983; Mesulam and Geula, 1988) is heavily populated (90% of cell bodies) by cortically projecting cholinergic neurons (Mesulam et al., 2004) which are also known for their extremely long and complex branching; the full arborization length of a single neuron was estimated in humans at >100 meters (Wu et al., 2014) . Like the layer II entorhinal spiny projection neurons, the cortical cholinergic projection neurons of the basal forebrain accumulate Aβ and pTau early in the course of Alzheimer's disease, and as early as the third decade of life (Mesulam et al., 2004; Baker-Nigh et al., 2015) . Lending further support to early vulnerability of the basal forebrain to Alzheimer's disease, we previously found that longitudinal NbM degeneration was selectively increased in cognitively normal older adults with abnormal CSF biomarkers of Aβ, over and above age-related degeneration in cortical areas including entorhinal cortex (Schmitz and Spreng, 2016) . These initial findings raise the possibility that Alzheimer's disease pathology spreads from the basal forebrain to entorhinal cortex (NbM→EC), possibly via the same trans-synaptic mechanisms of tau spread proposed previously in the rodent research (Liu et al., 2012) . If true, the NbM→EC model would add a crucial 'upstream' link to the EC→Neocortical predictive pathological staging of Alzheimer's disease. Under this model, the ascending cholinergic projections from NbM first 'seed' the EC with tau pathology, thereby eventuating the pattern of temporoparietal neurodegeneration typically attributed to the earliest stages of Alzheimer's disease. Support for the NbM→EC model would have major clinical implications, motivating a shift toward preventative treatment strategies aimed at relieving agerelated pressures on the cortical cholinergic projection system.
Here we directly compared the NbM→EC and EC→NbM models of predictive pathological staging in a large sample of older adults ranging from cognitively normal to Alzheimer's dementia, and then examined if the results generalized to a second independent sample of adults spanning the same clinical diagnostic continuum. In each sample, we first integrated CSF biomarkers of Aβ and pTau neuropathology into a ratio pTau/AB and delineate two groups of older adults in each of the two samples using an independently defined ratio cutpoint which was recently cross-validated at ~90% sensitivity and specificity (Hansson 2018 , Schindler 2018 . Individuals below the cutpoint exhibit a 'neurotypical' biomarker-based phenotype of brain aging; individuals above the cutpoint exhibit an 'Alzheimer's pathological' phenotype. Because CSF pTau/AB is sensitive to the earliest abnormalities of AD (Jack et al 2013), we identified many cognitively normal adults falling above the cutpoint in both samples. We then tracked these groups with structural MRI (sMRI) indices of baseline gray matter volume and longitudinal neurodegeneration over a two-year period. Both the CSF and sMRI data were acquired from multiple phases of the Alzheimer 's disease Neuroimaging Initiative (ADNI).
To examine the 'spread' of degeneration between NbM and EC, we used a predictive modelling strategy which tests whether baseline gray matter volume in a seed region accounts for variation in subsequent longitudinal degeneration (change over future timepoints) in a target region. We determined whether evidence of predictive pathological spread favored either the NbM→EC or EC→NbM model, and whether this evidence generalized across the independent samples. We then determined whether CSF concentrations of pTau/Aβ moderated the observed predictive relationship, consistent with an underlying trans-synaptic mechanism of pathophysiological spread. Additional moderating factors, including clinical diagnosis, were evaluated in this framework. We then examined the selectivity of predictive pathological spread between NbM and EC using a whole-brain voxel-wise predictive modelling strategy. Finally, we used the same whole-brain strategy to test whether the EC→Neocortical model recapitulates the spread of neuropathology from EC to temporoparietal cortices observed in prior work (Liu et al., 2012; Khan et al., 2014) . If degeneration in the basal forebrain cholinergic projection system is a robust and reliable upstream event of entorhinal degeneration, then it should predict localized entorhinal degeneration, whereas entorhinal cortex should predict downstream events in temporal and parietal cortices.
Materials and methods

ADNI Data
Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD).
We used data from the ADNI-1 as first cohort and ADNI-GO and ADNI-2 combined (ADNI-GO/2) as second cohort. ADNI-1 was carried out in 1.5T MR scanners and ADNI-GO/2 in 3T MR scanners. All high-resolution T1 sMRI scans were downloaded from ADNI LONI (http://adni.loni.usc.edu/). A total of 502 ADNI-1 sMRI scans were downloaded from a standardized 2-years interval image collection. This data collection was created to minimize variability between studies and ensure a minimum quality control of the images (Wyman et al., 2014) . To obtain the ADNI-GO/2 sMRI scans, we first selected those subjects that had CSF biomarker data (see below) and searched by their research IDs (RIDs). We downloaded longitudinal sMRI images from 714 ADNI-GO/2 participants. To select the two longitudinal time points for each individual, we applied a bounded interval of a mean=1.5 years +/-12 months to maximize the inclusion of participants. 104 participants didn't have longitudinal sMRI data within the bounded interval. For ADNI sites with GE and Siemens scanners, we used images corrected for distortions (GradWarp) and B1 non-uniformity. For ADNI sites with Philips scanners, these corrections are applied at acquisition (see http://adni.loni.usc.edu/methods/mri-tool/mri-preprocessing/). Finally, to be able to compare ADNI-1 and ADNI-GO/2 data as two independent samples, we discarded participants from ADNI-GO/2 that also took part in the ADNI-1 studies (n=49), due to the smaller sample size of the ADNI1 cohort.
CSF biomarkers
Accumulation of brain Aβ in plaques and pTau in neurofibrillary tangles are the main neuropathological signs of AD. These biomarkers can be measured in the CSF and are able to differentiate Alzheimer's disease patients in good concordance with positron emission tomography classifications (Shaw et al., 2009; Hansson et al., 2018; Schindler et al., 2018) . CSF samples of Aβ and pTau from the baseline visit were produced with a fully-automated Elecsys protocol (see Supplementary section CSF procedures). We calculated a ratio of pTau/Aβ and used a standardized cut-off of 0.028, which was recently cross-validated between the ADNI and Swedish BioFinder studies (Hansson et al., 2018) to classify participants into abnormal (aCSF; pTau/Aβ >= 0.028) and a normal CSF groups (nCSF < 0.028). Using ratios of pTau over Aβ supersedes using single analytes to distinguish amyloid status using positron emission tomography (Schindler et al., 2018) . 216 participants from ADNI-1 didn't have CSF measures and were therefore not included. It is important to note that our grouping strategy is purely based on CSF biomarkers, independent of any cognitive or clinical diagnosis, though we follow-up with analyses of clinical diagnosis (see Results).
APOE genotyping
The ε4 allele of the APOE gene is the strongest genetic risk factor for non-familial Alzheimer's disease (Corder et al., 1993; Liu and Bu, 2013) and is thought to interact with the selective vulnerability of cholinergic BF neurons by disrupting the capacity of these cells to support and maintain their enormous axonal membranes (Poirier et al., 1993 (Poirier et al., , 1995 Poirier, 1994) . In order to study the effect of the CSF Alzheimer's disease biomarkers independently of other factors, we included the APOE genotype as a covariate of no interest in our analyses. The APOE information for all individuals with both sMRI and CSF data was obtained from the APOERES.csv spreadsheet and the ε4+ status was defined as having at least one ε4 allele. A blood sample at the screening or baseline visit was collected for APOE genotyping and genotype analysis was performed following standard procedures (Saykin et al., 2010) .
Neuropsychological assessment
Cognitive performance was assessed with a neuropsychological battery that covered a wide range of cognitive functions, including short and long-term memory, language, executive function and attention. We used baseline data from two composite scores, one for memory and one for executive function, derived from the ADNI neuropsychological battery that were recently validated using confirmatory factor analysis (Crane et al., 2012; Gibbons, 2012 
ADNI Clinical Diagnosis
At the baseline visit, an initial diagnosis recommended by the ADNI Clinical Core was used to classify participants into Cognitively Normal (CDR=0, MMSE 24-30), Mild Cognitively Impaired (CDR=0.5, MMSE 24-30) and Alzheimer's disease (CDR 0.5-1, MMSE 20-26) (Aisen et al., 2010 (Aisen et al., , 2015 Petersen et al., 2010) .
CSF groups by neuropsychological status
To confirm that our CSF grouping strategy differentiated participants based on measures of neuropsychological status, we collapsed the baseline neuropsychological data from both ADNI cohorts to compare the aCSF and nCSF groups on the Mini Mental State Examination, a common test of general cognitive function, as well as the two composite scores of memory and executive function (see preceding section). For each test, we computed one way fixed effects ANOVAs with CSF group (aCSF, nCSF) as a factor, covarying for Age, Sex, Education, Cohort and APOE genotype. These models revealed significant main effects of CSF pathology on cognition in all tests. Consistent with the sensitivity of CSF pTau/Aβ to pathological aging, the aCSF group exhibited significantly more cognitive impairment than the nCSF group on Mini Mental State Examination, memory and executive function. See Table 1 . 
Longitudinal structural MRI
A serial longitudinal pipeline scheme in SPM12 r7219 (https://www.fil.ion.ucl.ac.uk/spm/) implemented in Matlab 2013a was used to calculate the GM volume changes from the sMRI data (Ashburner and Ridgway, 2013) . This procedure unifies rigid-body registration, intensity inhomogeneity correction and non-linear diffeomorphic transformation in a single iterative model.
Initially, all of the individual time-points were co-registered to the ICBM 152 volume to ensure good starting parameters for the high-dimensional DARTEL warping algorithm. We then employed within-subject symmetric diffeomorphic registration of the two timepoints to create a midpoint average T1-image for each subject. Computing a mid-point average image prevents introduction of biases associated with using individual time-points as the reference (e.g., results
differ depending of the time-point that is used as a reference). The mid-point average was scaled by the interscan interval. The registration step produced Jacobian determinant maps, which index contractions and expansions for each time-point relative to the mid-point average image. The default parameters for noise estimation, warping and bias regularizations were used. The mid-point average images were then segmented using SPM's unified segmentation with the following settings: light regularization, 60mm of FWHM gaussian smoothness of bias and 2,2,2,3,4,2 Gaussians per tissue type. The resulting 1.5mm 3 GM and white matter maps were used to create separate DARTEL group templates for each sample (ADNI-1, and ADNI-GO/2). The DARTEL algorithm improves the inter-subject alignment by using multiple parameters per voxel when aligning the images (Ashburner, 2007) . The segmented GM maps were multiplied by the Jacobian determinants of each time-point (Mechelli et al., 2005) . We then warped the segmented GM and white matter maps into the DARTEL template space with the 'preserve amount' option. Default settings were used elsewhere. The warping step produced modulated GM and white matter volumetric maps for each timepoint.
To check the quality of the images for subsequent analyses, the warped, modulated GM maps of each timepoint were visually inspected for segmentation and normalization inaccuracies by creating a plot showing a slice for all the subjects and were inspected for the presence of outliers by calculating the correlation between all the volumes using the CAT12 toolbox (http://dbm.neuro.uni-jena.de/cat/). Subjects that exhibited a correlation below 2 standard deviations and abnormalities on their segmented GM volume (e.g. low signal intensity, inhomogeneities, warping errors) were excluded. Two subjects were discarded due to low data quality in ADNI-1 and eight in ADNI-GO/2. See Table 2 for complete information of the included participants. 
ROI definition
To test the predictive pathological models between the NbM and EC, we extracted GM volumes from two regions of interest (ROIs) using probabilistic atlases. Bilateral anatomical ROIs were created in MNI space with the SPM Anatomy Toolbox r 2.2b (http://www.fz-juelich.de/inm/inm-1/DE/Forschung/_docs/SPMAnatomyToolbox/SPMAnatomyToolbox_node.html) using previously published probabilistic maps of the NbM (Zaborszky et al., 2008) and the EC (Amunts et al., 2005) . The NbM ROI is equivalent to areas Ch4 and Ch4p (Mesulam, 1983; Mesulam and Geula, 1988) . The ROIs were then resampled and warped to the DARTEL group template (see Fig. 1b ). Estimates of modulated GM volume (in units of milliliters) at each time-point were obtained using the ROI as a masking region, and by summing the total intensity of voxels falling within the masking region adjusted for the size and number of voxels (http://www0.cs.ucl.ac.uk/staff/g.ridgway/vbm/get_totals.m). No spatial smoothing was applied to the volumes. In addition, the total gray matter (TGM) from the modulated and warped individual time points was calculated using the same procedure. The total intracranial volume (TICV) was computed by summing up the tissue volumes of GM, white matter and CSF of the segmented average images produced in a previous step using the *seg8.mat file from the segmentation (Malone et al., 2015) .
In order to assess longitudinal changes in GM volumes, annualized percent change (APC) from baseline was calculated with the following formula (Cavedo et al., 2017) : (Liu et al., 2012) .
Statistical Analyses
ANOVA: To compare baseline volumes and longitudinal volume changes between the CSF groups, we computed fixed effects ANOVAs for each ADNI cohort and each ROI with CSF Group (aCSF, nCSF) as a factor covarying for Age, Sex, Education, TICV, baseline TGM and APOE genotype (see Supplementary Fig. 1 for the bivariate correlation values among the modeled variables). We then pooled the data from both ADNI Cohorts and computed one way fixed effects ANOVAs with CSF group (aCSF, nCSF) as a factor, correcting for the same covariates, and an additional covariate for study Cohort (Ma et al., 2018) . All ANOVA models were carried out in R with a type III sums of squares. Moderation analyses of independent samples: The moderation analyses ( Fig. 3e and 3j ) were carried out using the PROCESS macro for SPSS (Hayes, 2012) Comparison of correlations between dependent samples: To compare correlation coefficients between the NbM→EC and EC→NbM models, we used cocor to account for the dependence between the two models (Diedenhofen and Musch, 2015) .
Whole-brain analysis
To investigate the anatomical specificity of the relationship between baseline NbM volumes and longitudinal degeneration in the EC, we pursued an exploratory whole brain voxel-wise analysis.
Whole-brain APC maps were calculated with the previous APC formula with the imcalc tool in SPM12. The APC maps were smoothed with a 4mm FWHM Gaussian kernel (Grothe et al., 2012; Cantero et al., 2017) . For exploratory purposes, we tested a model with baseline EC predicting APC in every voxel in the aCSF group pooled across the ADNI-1 and ADNI-GO/ADNI-2 datasets.
These regression models were estimated with non-parametric permutation testing using the Statistical NonParametric Mapping toolbox v13 (http://warwick.ac.uk/snpm) for SPM12 (Nichols and Holmes, 2002) . Age, Sex, Education, TICV, baseline TGM, APOE genotype and Cohort were included as covariates. The models were estimated with 5000 permutations, without variance smoothing and global normalization, and including an explicit mask of the binarized and thresholded (>0.1) DARTEL GM ADNI-GO/2 group template. Results are presented with a voxellevel threshold of p<0.05 Family-Wise Error (FWE) corrected for multiple comparisons across the brain.
Data availability
The data that support the findings of this study are openly available for request in LONI at https://ida.loni.usc.edu/login.jsp
Results
Abnormal CSF pTau/Aβ differentiates MRI indices of NbM and EC neurodegeneration
We first examined how the CSF pTau/Aβ grouping criteria differentiates patterns of baseline NbM and EC volume. Consistent with the sensitivity of CSF to neuropathology, we found that individuals with abnormal CSF cut-offs had smaller baseline volumes in the NbM in the ADNI-1 (main effect of CSF Group: F1,276=9.04, p=0.002), ADNI-GO/2 (main effect of CSF Group:
F1,594=78.16, p<0.001) and in the pooled data of both cohorts (main effect of CSF Group:
F1,828=75.88, p<0.001; Fig 2a) . Baseline volumes of the EC were also smaller in the aCSF group in ADNI-1 (main effect of CSF Group: F1,276=8.71, p=0.003), ADNI-GO/2 (main effect of CSF Group: F1,594=21.98, p<0.001) and in the pooled data (main effect of CSF Group: F1,828=25.86, p<0.001; Fig 2b) .
We next examined if the CSF pTau/Aβ grouping criteria influenced longitudinal indices of APC in the NbM and EC at each ADNI Cohort. These models revealed that individuals with abnormal CSF biomarkers showed more longitudinal atrophy in the NbM in the ADNI-GO/2 (main effect of CSF Group: F1,594=7.60, p=0.005) and in the pooled dataset (main effect of CSF Group:
F1,828=9.79, p=0.002), but not in ADNI-1 (main effect of CSF Group: F1,276=2.54, p=0.11; Fig   2c) . In the EC, the aCSF group exhibited more longitudinal atrophy in ADNI-1 (main effect of CSF Group: F1,276=23.91, p<0.001), ADNI-GO/2 (main effect of CSF Group: F1,594=29.54, p<0.001) and in the pooled data (main effect of CSF Group: F1,828=47.51, p<0.001; Fig 2d) .
Finally, we investigated if the magnitude of longitudinal degeneration in the NbM and in the EC differed between individuals at different disease stages. For that, we cross-referenced the CSF groups with the ADNI baseline Clinical Diagnosis and found that, individuals with abnormal CSF biomarkers in all disease stages had increased degeneration in the NbM and the EC. Crucially, individuals in the preclinical disease stage (aCSF and normal cognition at baseline) showed greater magnitudes of degeneration in the NbM and the EC compared to the cognitively normal controls (nCSF and normal cognition at baseline). See Supplementary Fig. 2 and Supplementary Table 1 .
Consistent with our hypotheses, CSF biomarkers of abnormal pTau/Aβ accumulation in the central nervous system differentiated both baseline gray matter volume and longitudinal gray matter degeneration in the NbM and EC. 
Abnormal pTau/AB potentiates the predictive spread of NbM→EC degeneration
Thus far, our multimodal CSF and structural MRI analyses have treated patterns of neurodegeneration in the NbM and EC separately. We next used regression-based modelling to test if the degeneration in the NbM and in the EC reflects interdependent pathological processes. We used robust linear regression to examine these competing models in the aCSF and nCSF groups. Consistent with an interdependent NbM→EC model, we found in the aCSF group that baseline NbM volumes predicted longitudinal degeneration in the EC in both ADNI-1 ( Fig. 3a; r=0.20, t166=2.12, p=0.03) and ADNI-GO/2 ( Fig. 3b; r=0 .37, t308=5.15, p<0.001). We next examined whether the predictive pathological staging of NbM and EC degeneration is observable under conditions of normal CSF pTau/Aβ. It could be the case that the underlying neuropathological process driving this relationship also occurs at 'neurotypical' levels of pTau/Aβ, but that this process is exacerbated in the aCSF group. In this case, we would expect to observe the same NbM→EC interrelationship, though possibly at a smaller magnitude. We found negligible evidence for the NbM→EC model in the nCSF group in ADNI-1 ( Fig.3c ; r=-0.17, t102=-1.14, p=0.25). However, we did observe a predictive relationship in ADNI-GO/2 (Fig.3d, r=0 .21, t229=2.47, p=0.01). We then examined these relationships in the pooled data. The results supported the NbM→EC model in the aCSF (r=0.30, t481= 5.32, p<0.001) but not the nCSF group (r = 0.11, t338=1.45, p=0.14). See Figure 3e and Supplementary Table 2 . To exclude the possibility that the results were distorted by possible collinearities among the model predictors and covariates, we computed each model without any of the covariates. The exclusion of covariates did not alter any of the above findings (see Supplementary Table 3 ). To directly test if the relationship observed in the pooled aCSF group was significantly different from the that observed in the pooled nCSF group, we computed a moderation analysis with CSF group (aCSF, nCSF) as a dichotomous moderator on the NbM→EC interrelationship (see Methods). We found a significant moderating effect of CSF group on the NbM→EC interrelationship (t826=2.55, p=0.01), indicating a more pronounced interregional spread in the aCSF compared to the nCSF group.
We next tested the competing model of EC→NbM predictive pathological spread, focusing first on the aCSF group. We found that EC baseline volumes did not predict longitudinal decreases in the NbM in ADNI-1 ( Fig. 3f ; r=-0.06, t166=-0.56, p=0.57), in ADNI-GO/2 ( Fig. 3g; r=0 .10, t308=1.18, p=0.23) or in the pooled sample ( Fig.3j; r=0 .02, t481=0.26, p=0.79; Supplementary Table   1 ). Moreover, we found negligible evidence for the EC→NbM model in the nCSF group in ADNI-1 ( Fig.3h; r=0.12, t102=0.92, p=0.36) , ADNI-GO/2 (Fig.3i, r=0.18, t229=1.72, p=0.08) , or in the pooled sample ( Fig.3j; r=0.12, t334=1 .53 , p=0.12; Supplementary Table 1 ). Nor was there a significant interaction between CSF group and the relationship between EC and NbM in the pooled sample (Fig 3j; t826=1, p=0.62) .
We then directly compared the two predictive staging models, NbM→EC and EC→NbM, using a slopes analysis between dependent samples (see Methods). We found that the coefficients in each model were significantly different from one another in the aCSF group (z = 5.54; p<0.001; 95% r CI: 0.1831-0.3847) but not in the nCSF group (z = 0.08; p=0.931; 95% r CI: -0.1424 -0.13). See 
Clinical diagnosis does not moderate the relationship between NbM→EC
Having demonstrated that the NbM→EC relationship was more prominent and reliable in the aCSF group, we then investigated whether the severity of the disease had an impact on the strength of this relationship in the pooled aCSF group. We expected that in initial (i.e. cognitively normal aCSF individuals) and advanced disease stages (i.e. cognitively impaired aCSF individuals), participants would show a weaker predictive relationship due to smaller magnitudes of EC atrophy in the early stages and reduced NbM atrophy in the more advanced stages (Schmitz and Spreng, 2016) . Clinical diagnosis was not a significant moderating effect ( Supplementary Figure 3; t1,479=1.65, p=0.49), indicating that the predictive relationship was robust across clinical diagnostic subgroups of the aCSF cohort.
NbM→EC predictive pathological spreading is anatomically specific
How spatially selective is the observed interrelationship between NbM and EC in the aCSF group?
To determine where degeneration is predicted based on NbM integrity, we performed a voxel-wise regression analysis between baseline volumes in the NbM and longitudinal APC in every brain voxel (see Methods). The model collapsed aCSF individuals across the two ADNI Cohorts into a single cohort. We found that baseline NbM volumes predicted degeneration in a circumscribed cluster of regions localized to the right entorhinal and perirhinal cortices and in the left middle temporal gyrus (Fig. 5a ). The predictive pathological spread of NbM→EC neurodegeneration therefore exhibits a high degree of anatomical specificity.
In our a priori ROI-based regression models, we found negligible evidence in support of the EC→NbM model. However, following from non-human animal work (Khan et al., 2014) , we hypothesized that that predictive pathological spread of degeneration from EC might target anatomically and functionally connected cortical areas including the parahippocampal and posterior parietal cortices. To test this hypothesis, we computed a second voxel-wise regression analysis in the pooled aCSF group between baseline volumes in the EC and longitudinal APC in every brain voxel of the gray matter mask (see Methods). We found that baseline EC volumes predicted longitudinal degeneration in a circumscribed network of temporal cortical regions including the entorhinal, perirhinal, parahippocampal and fusiform cortices and temporal poles ( Figure. 5b) . Additional clusters were detected in the insular and posterior parietal cortices.
Finally, we tested the same models in the nCSF cohort, collapsing individuals from both ADNI Cohorts. No significant voxels were found at the corrected statistical threshold (p<0.05 FWE) in either of the models (NbM→whole brain; EC→whole brain). Taken together, the voxel-wise regression results show that among individuals expressing abnormal CSF: (1) baseline NbM volumes selectively predict degeneration in the EC and adjacent perirhinal cortex, and, (2) EC degeneration 'spreads' to anatomically and functionally connected areas including the parahippocampal gyrus and other temporoparietal regions (Khan et al., 2014) . 
Discussion
We provide evidence that degeneration in the NbM is an upstream event of subsequent degeneration in the EC and temporal cortices. Our results generalized across two non-overlapping and well-powered datasets. As hypothesized, the NbM→EC relationship was moderated by the presence of abnormal CSF biomarkers of pTau and Aβ, consistent with a mechanism of transsynaptic spread of these proteins across anatomically connected regions. Using whole-brain regression models, we presented novel evidence that the relationship between baseline NbM volumes and neurodegeneration was spatially specific to regions of the EC and the perirhinal cortices, regions hypothesized to be among the earliest to be affected in Alzheimer's disease (Braak and Braak, 1991; Khan et al., 2014) . Finally, baseline EC volumes predicted neurodegeneration mainly in regions of the temporal cortex, recapitulating the prevailing staging model (Braak and Braak, 1991; Braak et al., 2006; Liu et al., 2012) . These findings highlight the relevance of the cholinergic BF nuclei in Alzheimer's disease and motivate novel interventions targeted to these neuronal populations.
The intrinsic properties of the BF cholinergic neurons, including their location, connections and morphology, might be key to understanding why these cell types are selectively vulnerable in Alzheimer's disease (Mattson and Magnus, 2006) . The NbM cholinergic neurons have large projecting axons with extensive arbors that expand long distances in the central nervous system (Wu et al., 2014; Ballinger et al., 2016) . Extremely large axons and arbors exert high metabolic demands in order to support their maintenance, repair and transport. A less efficient cellular response to axonal perturbations could increase their vulnerability to the accumulation of abnormal proteins (Wu et al., 2014) . In addition, large surface areas increase their exposure to toxic environments (Mattson and Magnus, 2006) . Consistent with its selective vulnerability, the NbM is one of the most vulnerable regions to the early accumulation of intracellular tau pathology (Mesulam et al., 2004; Del Tredici, 2011) and , interestingly, intraneuronal amyloid oligomers (Baker-Nigh et al., 2015) . There is increasing evidence showing that intraneuronal amyloid can have deleterious early effects in the cells, such as disrupting their retrograde axonal transport machinery (Morfini et al., 2009 ) which in turn can cause a neurotrophic deficiency (Bellucci et al., 2006) leading to neurodegeneration (De Lacalle et al., 1996) . In vivo structural MRI studies have added further support for the vulnerability of the BF, showing reduced BF volumes cross-sectionally (Grothe et al., 2012; Cantero et al., 2017) and longitudinally (Hall et al., 2008; Grothe et al., 2013; Schmitz et al., 2018) in individuals in the Alzheimer's disease continuum.
In this study, the pathological spread of neurodegeneration from the NbM to the EC was exacerbated in individuals with abnormal levels of CSF pTau and Aβ. Evidence from non-human animal studies shows that protein aggregates can spread trans-synaptically to neuroanatomically connected regions. In an amyloid precursor protein mouse model of Alzheimer's disease, neuronal accumulation of Aβ was observed first in the EC, followed by the dentate gyrus, a downstream region receiving monosynaptic projections from the EC (Harris et al., 2010) . Evidence further suggests that tau aggregates propagate from the EC to limbic and then neocortical connected areas (De Calignon et al., 2012; Kfoury et al., 2012; Walker et al., 2013; Wu et al., 2016) . For example, in mice that expressed human tau restricted to the EC, the axonal terminals of the EC projecting neurons showed increasing markers of tauopathy over time (Liu et al., 2012) . In all, this shows that Aβ and tau can propagate synaptically across neural networks of anatomically connected vulnerable cells. If the NbM is one of the earliest regions to accumulate tau and Aβ, then these proteins may spread to the EC trans-synaptically, inducing the observed downstream neurodegeneration. Our results are therefore compatible with animal research showing a transsynaptic mechanism of abnormal spreading of tau proteins. However, to ultimately demonstrate that degeneration in the EC is driven by the spread of tau pathology from the NbM in humans, longitudinal studies integrating both structural MRI and tau positron emission tomography are needed. In addition, we observed a relationship between the NbM→EC in the normal CSF group.
This effect was weaker and not reliable across samples, indicating the possibility that there are other age-related pressures on the NbM cholinergic neurons independent from Aβ and pTau (Nitsch et al., 1992; Wurtman, 1992) .
Using longitudinal whole-brain structural MRI, we also showed a reliable ( Figure 3A -E) and
highly specific ( Figure 5A ) sequence of neurodegeneration from the NbM to the EC. This result challenges the most widely accepted model of Alzheimer's disease staging, which posits that the neuropathological and neurodegenerative cascade initiates in the transentorhinal and EC (Braak and Braak, 1991; Corder et al., 2000; Braak et al., 2006; Liu et al., 2012; Khan et al., 2014) . This model was primarily advanced from post-mortem histology studies that examined the brains of individuals who died at different ages from different causes, which showed tau aggregates forming in the EC even in non-demented individuals (Braak and Braak, 1991; Braak et al., 2006) .
Predictive pathological staging based on histological strategies are limited by the heterogeneity of the post-mortem samples, the inability to track pathology with progressive neurodegeneration within individuals, the variability in tissue staining techniques used to profile underlying pathology, and the variability in anatomical coverage across both cortical and subcortical regions.
We overcame these limitations by using an in vivo longitudinal neuroimaging strategy of predictive pathological staging in a large cohort of over 800 older adults. We quantified the baseline CSF profile of amyloid and tau pathology in each individual based on the automated Elecsys protocol, which was harmonized between samples. We then applied an independently defined cutpoint to delineate unbiased groups of individuals exhibiting abnormal and normal CSF biomarkers. By comparing the spreading dynamics of neurodegeneration between these two groups, we demonstrated that baseline NbM volumes predicted an accelerated annual rate of degeneration in a future time point in the EC in the presence of abnormally elevated Aβ and pTau. In addition, we found evidence that this neuropathological background was associated with neurodegenerative spreading from EC to targets of its projections in the medial temporal lobes. These latter findings parallel those of recent cross-species translational research comparing transgenic mouse models of Alzheimer's disease with at-risk human participants (Khan et al., 2014) . In all, our results added evidence that NbM degeneration is an earlier pathological event in the Alzheimer's disease pathological cascade.
Here, we showed that the NbM→EC model reliably generalized between two different populations. It is important to note that the data of the ADNI-GO/2 sample were acquired in 3T and the ADNI-1 in 1.5T scanners. Previous reports have only used 1.5 datasets (Schmitz and Spreng, 2016) and it is well known that the signal to noise ratio of subcortical structures is higher at 3T (Tardif et al., 2010; Marchewka et al., 2014) . It is therefore likely that degeneration in the NbM is more accurately quantified in the ADNI-GO/2 sample. Although it is estimated that approximately 90% of the NbM neurons in monkeys are cholinergic (Mesulam, 1983) , to ultimately prove that the degeneration in the EC is driven by a cholinergic deficit in humans, degeneration that is specific to cholinergic cell types should be demonstrated. The combination of structural MRI with cholinergic positron emission tomography (Aghourian et al., 2017; Schmitz et al., 2018) could help elucidate this issue. Finally, late onset Alzheimer's disease is a complex, multifactorial (Veitch et al., 2018) , polygenic (Tan et al., 2019) In conclusion, the current study provides reliable and anatomically specific support for a predictive pathological staging model of Alzheimer's disease that progresses in the following sequence:
NbM→EC→Neocortex. In all, our findings call into question the prevailing view of Alzheimer's disease pathogenesis, suggesting instead that degeneration of the basal forebrain cholinergic projection system is an upstream event to that of its most vulnerable cortical targets in the EC. If the cholinergic neurons of the BF are selectively vulnerable to the early accumulation and propagation of Alzheimer's disease pathology, then interventions targeting these neuronal populations in early disease stages may be useful for modifying disease progression prior to cognitive decline. 
